Advertisement

Topics

Kyowa Hakko Kirin Co. Ltd. Company Profile

21:14 EST 18th December 2018 | BioPortfolio


News Articles [113 Associated News Articles listed on BioPortfolio]

Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Tokyo, Japan, May 30, 2018 –Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151 President and COO: Masashi Miyamoto, “Kyowa Hakko Kirin”) announced today that it has been notified that the U.S. Food and Dr...

Kyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175

Kyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance ReportSummaryKyowa Hakko Kirin Co., Ltd. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and i...

Kyowa Kirin gibt positive Stellungnahme des CHMP zu Mogamulizumab zur Behandlung von Mycosis fungoides und Sézary-Syndrom bekannt

Tokio (ots/PRNewswire) - Mogamulizumab wäre nach Zulassung der erste biologische Wirkstoff gegen CCR4 für Patienten in Europa. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin), hat heute bekanntgegeben, ....

EU approves Kyowa Kirin's drug for rare lymphoma

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is manufactured by Japanese firm Kyowa Hakko Kirin (Kyowa Kirin), and ...

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has rec...

Kyowa Hakko Kirin gets rights to MEI's PI3K inhibitor

MEI Pharma Inc. granted Kyowa Hakko Kirin Co. Ltd. exclusive rights to develop and sell its PI3K delta inhibitor ME401 in Japan.

FDA Approves Kyowa Kirin’s Poteligeo for Treatment of Two Rare Types of Non-Hodgkin Lymphoma

TOKYO, Aug. 8, 2018 /PRNewswire/ — Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Poteligeo® (mogamulizumab...

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin and Kyowa Kirin In...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [17 Associated Companies listed on BioPortfolio]

Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co., Ltd.

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko

Kyowa Hakko USA

More Information about "Kyowa Hakko Kirin Co. Ltd." on BioPortfolio

We have published hundreds of Kyowa Hakko Kirin Co. Ltd. news stories on BioPortfolio along with dozens of Kyowa Hakko Kirin Co. Ltd. Clinical Trials and PubMed Articles about Kyowa Hakko Kirin Co. Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko Kirin Co. Ltd. Companies in our database. You can also find out about relevant Kyowa Hakko Kirin Co. Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record